234 related articles for article (PubMed ID: 11900573)
1. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis.
Ruhul Quddus M; Latkovich P; Castellani WJ; James Sung C; Steinhoff MM; Briggs RC; Miranda RN
Arch Pathol Lab Med; 2002 Apr; 126(4):459-63. PubMed ID: 11900573
[TBL] [Abstract][Full Text] [Related]
2. Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables.
Ozuysal S; Oztürk H; Bilgin T; Filiz G
Arch Gynecol Obstet; 2005 Feb; 271(2):123-6. PubMed ID: 14740230
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis.
Nishimura Y; Watanabe J; Jobo T; Kato N; Fujisawa T; Kamata Y; Kuramoto H
Anticancer Res; 2004; 24(4):2185-91. PubMed ID: 15330159
[TBL] [Abstract][Full Text] [Related]
4. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas.
Cao QJ; Einstein MH; Anderson PS; Runowicz CD; Balan R; Jones JG
Int J Gynecol Pathol; 2002 Apr; 21(2):147-54. PubMed ID: 11917224
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium.
Shevra CR; Ghosh A; Kumar M
J Postgrad Med; 2015; 61(1):15-20. PubMed ID: 25511212
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and immunohistochemical characterization of papillary proliferation of the endometrium: A single institutional experience.
Park CK; Yoon G; Cho YA; Kim HS
Oncotarget; 2016 Jun; 7(26):39197-39206. PubMed ID: 27322430
[TBL] [Abstract][Full Text] [Related]
7. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
[TBL] [Abstract][Full Text] [Related]
8. Progressive derailment of cell cycle regulators in endometrial carcinogenesis.
Horrée N; van Diest PJ; van der Groep P; Sie-Go DM; Heintz AP
J Clin Pathol; 2008 Jan; 61(1):36-42. PubMed ID: 17483252
[TBL] [Abstract][Full Text] [Related]
9. Expression of Cyclin D1 in Hyperplasia and Carcinoma of Endometrium and Its Correlation with Histologic Grade, Tumor Type, and Clinicopathological Features.
Sangwan K; Garg M; Pathak N; Bharti L
J Lab Physicians; 2020 Dec; 12(3):165-170. PubMed ID: 33268933
[No Abstract] [Full Text] [Related]
10. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
[TBL] [Abstract][Full Text] [Related]
11. Immunoexpression of Cyclin D1 and PTEN in Various Endometrial Pathologies.
Shawana S; Kehar SI; Masood S; Aamir I
J Coll Physicians Surg Pak; 2016 Apr; 26(4):277-82. PubMed ID: 27097697
[TBL] [Abstract][Full Text] [Related]
12. p16 is consistently expressed in endometrial tubal metaplasia.
Horree N; Heintz AP; Sie-Go DM; van Diest PJ
Cell Oncol; 2007; 29(1):37-45. PubMed ID: 17429140
[TBL] [Abstract][Full Text] [Related]
13. Significantly decreased P27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression).
Ozkara SK; Corakci A
Pathol Oncol Res; 2004; 10(2):89-97. PubMed ID: 15188025
[TBL] [Abstract][Full Text] [Related]
14. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1.
Xu YY; Wu HJ; Ma HD; Xu LP; Huo Y; Yin LR
FEBS J; 2013 Aug; 280(16):3768-79. PubMed ID: 23731275
[TBL] [Abstract][Full Text] [Related]
16. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance.
Sivridis E; Giatromanolaki A; Koukourakis MI; Georgiou L; Anastasiadis P
Histopathology; 2002 Jan; 40(1):92-100. PubMed ID: 11903603
[TBL] [Abstract][Full Text] [Related]
17. p53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding.
Quddus MR; Sung CJ; Zheng W; Lauchlan SC
Histopathology; 1999 Jul; 35(1):44-9. PubMed ID: 10383713
[TBL] [Abstract][Full Text] [Related]
18. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
19. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
20. Hyperplasia and carcinoma in secretory endometrium: a diagnostic challenge.
Truskinovsky AM; Lifschitz-Mercer B; Czernobilsky B
Int J Gynecol Pathol; 2014 Mar; 33(2):107-13. PubMed ID: 24487463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
